Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...
India has a strong pharma network, with more than 10,000 manufacturing facilities, over 3,000 pharma companies.
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback